Dec 19 (Reuters) - Aldeyra Therapeutics said on Tuesday its experimental drug to treat a type of chronic skin disease was safe and well tolerated in a mid-stage study. (Reporting by Mariam Sunny and Puyaan Singh in Bengaluru' Editing by Anil D'Silva)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | -4.31% | -9.38% | +7.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.41% | 224M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics' eczema drug succeeds in mid-stage study